Compare UK prices. 40+ products · 17 retailers scored
PeptideClear UK

Cosmetic peptide head to head

GHK-Cu vs Matrixyl 3000

GHK-Cu has the deeper evidence base and is the most-studied cosmetic peptide. Matrixyl 3000 is the most commercially recognised. Both work via different signalling pathways. Layer them in separate steps rather than picking one or the other if your routine has room.

GHK-Cu Matrixyl 3000
Class Single peptide bound to copper Branded blend (palmitoyl tripeptide-1 + tetrapeptide-7)
Discovered / developed Pickart, 1973 Sederma, 2000s
Mechanism Activates copper-dependent enzymes, supports collagen and elastin synthesis, calms inflammation Triggers wound healing pathway, signals collagen and glycosaminoglycan production
Evidence base Decades of in-vitro and topical human research, mostly Pickart group plus independent labs Manufacturer-led RCTs, plus some independent topical studies
Effective topical concentration 0.1 to 1% across studies 3 to 8% of trade ingredient (~0.05 to 0.1% of named peptides)
Stable in Neutral to slightly alkaline pH Neutral pH, hydrated formulas
Pairs poorly with Vitamin C in same step (low pH degrades), strong AHAs in same step Same. Most peptides degrade in low pH
Pairs well with Hyaluronic acid, niacinamide (separate steps), ceramides Hyaluronic acid, niacinamide, peptide complexes
Strongest claim Most-studied cosmetic peptide. Strongest evidence base. Most commercially recognised. Strong marketing reach.

Which to pick if you can only pick one

  • · **Pick GHK-Cu** if you want the strongest evidence base and you trust ingredient-led skincare brands. The blue-green tint of copper-peptide serums is real (it is the copper).
  • · **Pick Matrixyl 3000** if your routine is already busy and you want a peptide complex with brand recognition. The Ordinary Matrixyl 10% + HA is the price-leader UK formulation.
  • · **Layer both** if your routine has room. Different mechanisms, complementary signalling.

See our individual category pages: GHK-Cu and Matrixyl 3000.

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-18